Skip Navigation


Rheumatology Advance Access originally published online on January 11, 2005
Rheumatology 2005 44(3):269-270; doi:10.1093/rheumatology/keh527
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/3/269    most recent
keh527v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kennedy, T. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kennedy, T. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 44 No. 3 © British Society for Rheumatology 2005; all rights reserved

EDITORIAL

The BSR Standards Guidelines and Audit Working Group (SGAWG)

T. D. Kennedy

Royal Liverpool and Broadgreen University Hospital, Rheumatology & AMAU, Liverpool, UK. E-mail: TomDken@hotmail.com

Chair of SGAWG on behalf of the Working Group, which is a subcommittee of BSR's Clinical Affairs Committee.

The first 10% of the full text of this article appears below.

Following the success of the report by the working party of the British Society for Rheumatology (BSR) on guidelines for prescribing TNF-{alpha} blockers in adults with rheumatoid arthritis [1], the BSR decided to set up a committee to develop further standards and guidelines. The NHS, through a variety of bodies, including NICE and the National Service Frameworks, use the vehicle of guidelines and standards to improve the quality of care for patients with a number of different diseases, most noticeably myocardial infarction [2], stroke [3] and diabetes mellitus [4]. Audit is the tool by which . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
L. J. Kay, I. D. Griffiths, and for the BSR Biologics Register Management committe
UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register
Rheumatology, November 1, 2006; 45(11): 1376 - 1379.
[Abstract] [Full Text] [PDF]